Compare DLNG & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLNG | CNTN |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Greece | United States |
| Employees | N/A | 3 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.0M | 184.2M |
| IPO Year | N/A | 2022 |
| Metric | DLNG | CNTN |
|---|---|---|
| Price | $4.14 | $3.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 137.8K | ★ 461.9K |
| Earning Date | 03-13-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.10 | N/A |
| P/E Ratio | $3.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $3.15 |
| 52 Week High | $4.45 | $5.27 |
| Indicator | DLNG | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 26.62 |
| Support Level | $3.46 | N/A |
| Resistance Level | $4.16 | $3.51 |
| Average True Range (ATR) | 0.22 | 0.30 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 56.67 | 0.93 |
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.